- Synaffix providing access to proprietary ADC technologies (GlycoConnect™, HydraSpace™ and exatecan-based SYNtecan E™ linker payloads)
- Emergence Therapeutics reserves rights to develop multiple ADCs against undisclosed targets to enhance its ADC pipeline
- Emergence Therapeutics becomes the 10th company to license the Synaffix ADC technology platform, with the largest total $360 millionand commercial sales royalties
Amsterdam, September 6, 2022 /PRNewswire/ — Synaffix BV (Synaffix) and Emergence Therapeutics AG (“Emergence”) (the “Companies”) today announce that they have entered into a maximum licensing agreement. $360 millionwhich provides Emergence access on a target-specific basis to Synaffix’s proprietary antibody-drug conjugate (ADC) technology. GlycoConnect™, HydraSpace™, and SYNtecan E™ linker payloads.
Under the terms of the agreement, Synaffix will provide up to $360 million Upfront and milestone payments plus commercial sales royalties. The first program will start upon signing, with the option to expand the collaboration to additional targets. The deal is the positive result of proof-of-concept data following a successful initial discovery research collaboration between the two companies.
Emergence will be responsible for the research, development, manufacturing and commercialization of ADCs. Synaffix will be responsible for manufacturing components specifically related to its proprietary technology.
Jack Elands, CEO of Emergence Therapeutics, commented: “This transaction demonstrates our commitment to developing a pipeline of first-in-class and/or best-in-class ADCs. We are actively moving forward with the program and we are impressed with the Synaffix technology and have selected it as a key component to accelerate our pipeline of ADCs to develop therapies for cancers with high unmet need. I’m glad you did.”
peter van de sandeSynaffix CEO said: “This is an important milestone for Synaffix.th ADC developers who license our innovative ADC technology and develop their own ADCs for their own pipelines. Integrating all critical technologies within his Synaffix has enabled repeatable development of his best-in-class and best-in-class ADCs under a single technology licensing agreement. We are thrilled that Emergence has chosen his Synaffix as our long-term ADC technology partner and look forward to working closely with Emergence as he builds his portfolio of ADC candidates. “
About Synapix BV
Synaffix BV is a biotechnology company that realizes ADC product candidates using its clinical-stage, site-specific ADC technology platform. In addition to GlycoConnect™ and HydraSpace™ technologies, the toxSYN™ linker payload platform completes a fully complementary technology platform allowing antibody-bearing companies to develop their own best-in-class ADCs under a single license from his Synaffix You can develop your product.
The Synaffix platform enables rapid timelines to clinic with an established supply chain for technology components. Granted patents covering Synaffix’ technology provide end-to-end protection for manufacturing technology and resulting products through at least 2035. Synaffix’s business model is the licensing of target-specific technology, as exemplified by its existing deal with ADC. Therapeutics, Mersana Therapeutics, Shanghai Miracogen, Innovent Biologics, ProfoundBio, Kyowa Kirin, Genmab, Macrogenics.
Synaffix is backed by a leading European life sciences focused investor syndicate including Aravis, BioGeneration Ventures, BOM Capital and M Ventures.
For more information, please visit www.synaffix.com.
About Emergence Therapeutics AG
Emergence Therapeutics is a European biopharmaceutical company developing novel antibody-drug conjugates (ADCs) to treat highly needed cancers. Its lead program combines highly specific antibodies with optimized linker and payload technology to target Nectin 4, an important target in a wide range of cancers. By the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Emergence Therapeutics is also actively developing a pipeline of first-in-class or best-in-class ADCs depending on therapeutic need. Emergence is supported by a network of the world’s leading experts in immuno-oncology and major international investor syndicates. Emergence Therapeutics AG is based in Duisburg. Germany have a subsidiary in Marseille, FranceSee below for more information.
About Synaffix ADC Platform Technology
Synaffix’s proprietary ADC technology platform consists of GlycoConnect™, HydraSpace™ and toxSYN™ technologies. Both GlycoConnect™ and HydraSpace™ are clinical-stage technologies that enable best-in-class ADCs with significantly improved efficacy and tolerability.
GlycoConnect™ is a conjugation technology that utilizes native antibody glycans for site-specific and stable payload attachment, tunable into DAR1, DAR2, or DAR4 formats. HydraSpace™ is a compact, highly polar spacer technology specifically designed to further enhance the therapeutic index with hydrophobic payloads. toxSYN™ is a linker payload platform that spans major validated MOAs for ADC product development, including SYNtecan E™ and SYNeamicin G™ among other linker payloads.
The combination of these three technologies provides developers with a “one-stop”, easy-to-use ADC technology platform, antibody developers to develop their own ADCs, and ADC developers to further expand their pipeline. You can increase your competitiveness.